Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Toward a Cure: Does Host Immunity Play a Role?

Zhang J, Crumpacker CS.

mSphere. 2017 Apr 26;2(2). pii: e00138-17. doi: 10.1128/mSphere.00138-17. eCollection 2017 Mar-Apr.

2.

Absence of exposure to varicella does not increase the risk of zoster.

Crumpacker CS 2nd.

Clin Infect Dis. 2011 Sep;53(5):411-2. doi: 10.1093/cid/cir439. No abstract available.

PMID:
21844023
4.

Invited commentary: human cytomegalovirus, inflammation, cardiovascular disease, and mortality.

Crumpacker CS.

Am J Epidemiol. 2010 Aug 15;172(4):372-4. doi: 10.1093/aje/kwq174. Epub 2010 Jul 21.

PMID:
20660119
5.

Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution.

Zhang J, Crumpacker CS.

Cell Res. 2010 Jul;20(7):745-7. doi: 10.1038/cr.2010.85. Epub 2010 Jun 22. No abstract available.

PMID:
20567263
6.

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.

PMID:
19648823
7.

Cytomegalovirus infection causes an increase of arterial blood pressure.

Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, Zhang J, Crumpacker CS.

PLoS Pathog. 2009 May;5(5):e1000427. doi: 10.1371/journal.ppat.1000427. Epub 2009 May 15.

8.

Valganciclovir and human herpesvirus-8.

Crumpacker CS.

J Infect Dis. 2008 Jul 1;198(1):6-7. doi: 10.1086/588821. No abstract available.

PMID:
18491975
9.

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.

PMID:
17721395
10.

Primitive hematopoietic cells resist HIV-1 infection via p21.

Zhang J, Scadden DT, Crumpacker CS.

J Clin Invest. 2007 Feb;117(2):473-81.

11.

Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis.

Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zhang J, Chu V, Hampton TG, Crumpacker CS, Abelmann WH, Amende I, Morgan JP.

Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1577-83. Epub 2005 May 27.

12.

Mixed glycoprotein B genotypes of cytomegalovirus and immunosuppression.

Crumpacker CS.

Clin Infect Dis. 2004 Jul 15;39(2):162-4. Epub 2004 Jun 23. No abstract available.

PMID:
15307022
13.

Use of antiviral drugs to prevent herpesvirus transmission.

Crumpacker CS.

N Engl J Med. 2004 Jan 1;350(1):67-8. No abstract available.

PMID:
14702430
14.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2003. A 50-year-old Colombian man with fever and seizures.

Crumpacker CS, Gonzalez RG, Makar RS.

N Engl J Med. 2003 Aug 21;349(8):789-96. No abstract available.

PMID:
12930932
15.

A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study.

Dezube BJ, Proper J, Zhang J, Choy VJ, Weeden W, Morrissey J, Burns EM, Dixon JD, O'Loughlin C, Williams LA, Pickering PJ, Crumpacker CS, Gelder FB.

J Infect Dis. 2003 Feb 1;187(3):500-3. Epub 2003 Jan 8.

PMID:
12552435
17.

New anti-HSV therapeutics target the helicase-primase complex.

Crumpacker CS, Schaffer PA.

Nat Med. 2002 Apr;8(4):327-8. No abstract available.

PMID:
11927930
18.

Cocaine enhances myocarditis induced by encephalomyocarditis virus in murine model.

Wang JF, Zhang J, Min JY, Sullivan MF, Crumpacker CS, Abelmann WH, Morgan JP.

Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H956-63.

19.
20.

Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Lurain NS, Weinberg A, Crumpacker CS, Chou S; Adult AIDS Clinical Trials Group-CMV Laboratories.

Antimicrob Agents Chemother. 2001 Oct;45(10):2775-80.

21.

A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a phase I study.

Dezube BJ, Dahl TA, Wong TK, Chapman B, Ono M, Yamaguchi N, Gillies SD, Chen LB, Crumpacker CS.

J Infect Dis. 2000 Aug;182(2):607-10. Epub 2000 Jul 28.

PMID:
10915097
22.

Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein.

Zhang JL, Sharma PL, Crumpacker CS.

Virology. 2000 Mar 15;268(2):251-63.

24.
25.

Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.

McSharry JJ, Lurain NS, Drusano GL, Landay AL, Notka M, O'Gorman MR, Weinberg A, Shapiro HM, Reichelderfer PS, Crumpacker CS.

Antimicrob Agents Chemother. 1998 Sep;42(9):2326-31.

26.

Expression of the CD8alpha beta-heterodimer on CD8(+) T lymphocytes in peripheral blood lymphocytes of human immunodeficiency virus- and human immunodeficiency virus+ individuals.

Schmitz JE, Forman MA, Lifton MA, ConcepciĆ³n O, Reimann KA Jr, Crumpacker CS, Daley JF, Gelman RS, Letvin NL.

Blood. 1998 Jul 1;92(1):198-206.

PMID:
9639517
27.

The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry.

Zhang JL, Choe H, Dezube BJ, Farzan M, Sharma PL, Zhou XC, Chen LB, Ono M, Gillies S, Wu Y, Sodroski JG, Crumpacker CS.

Virology. 1998 May 10;244(2):530-41.

28.

Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group.

Gnann JW Jr, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong SJ, Sherrill LC, DeHertogh DA, Whitley RJ.

Antimicrob Agents Chemother. 1998 May;42(5):1139-45.

29.

Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

Sharma PL, Crumpacker CS.

J Virol. 1997 Nov;71(11):8846-51. Erratum in: J Virol 1998 Apr;72(4):3504.

30.

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels.

Dezube BJ, Lederman MM, Chapman B, Georges DL, Dogon AL, Mudido P, Reis-Lishing J, Cheng SL, Silberman SL, Crumpacker CS.

J Infect Dis. 1997 Sep;176(3):807-10.

PMID:
9291340
31.

Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.

Zhang JL, Sharma PL, Li CJ, Dezube BJ, Pardee AB, Crumpacker CS.

Antimicrob Agents Chemother. 1997 May;41(5):977-81.

33.

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.

Balfour HH Jr, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Holm MA, Boivin G, Shepp DH, Crumpacker CS, Eaton CA, Martin-Munley SS.

Antimicrob Agents Chemother. 1996 Dec;40(12):2721-6.

34.

A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.

Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46.

PMID:
8898668
35.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J.

J Infect Dis. 1996 Oct;174(4):704-12.

PMID:
8843206
36.

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS.

J Infect Dis. 1996 Oct;174(4):696-703.

PMID:
8843205
37.

AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.

Sharma PL, Chatis PA, Dogon AL, Mayers DL, McCutchan FE, Page C, Crumpacker CS.

Virology. 1996 Sep 15;223(2):365-9. Erratum in: Virology 1996 Nov 15;225(2):428.

38.

Ganciclovir.

Crumpacker CS.

N Engl J Med. 1996 Sep 5;335(10):721-9. Review. No abstract available.

PMID:
8786764
39.
40.

Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood.

Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS.

J Infect Dis. 1995 Apr;171(4):1002-6.

PMID:
7706776
41.

Antiviral resistance in clinical practice.

Kimberlin DW, Crumpacker CS, Straus SE, Biron KK, Drew WL, Hayden FG, McKinlay M, Richman DD, Whitley RJ.

Antiviral Res. 1995 Apr;26(4):423-38. Review. No abstract available.

PMID:
7574544
42.

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.

D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD.

Ann Intern Med. 1995 Mar 15;122(6):401-8.

PMID:
7856987
43.

A rapid, direct test for zidovudine susceptibility in clinical isolates of human immunodeficiency virus type 1 (HIV-1) from infected children.

Lan Y, Japour AJ, Kim S, Welles SL, Crumpacker CS, Cooper E, Al-Attar I, McIntosh K.

Clin Diagn Virol. 1995 Mar;3(3):259-71.

PMID:
15566807
44.

Criteria for the diagnosis of infective endocarditis.

von Reyn FC, Arbeit RD, Friedland GH, Crumpacker CS 3rd.

Clin Infect Dis. 1994 Aug;19(2):368-70. No abstract available.

PMID:
7864961
45.
46.

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.

Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, et al.

Antimicrob Agents Chemother. 1994 Feb;38(2):307-14.

47.
48.

Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C.

Oyan AM, Dolter KE, Langeland N, Goins WF, Glorioso JC, Haarr L, Crumpacker CS.

J Virol. 1993 May;67(5):2434-41.

49.

Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.

Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB.

Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1839-42.

50.

HIV infection of the BS-1 human stroma cell line: effect on murine hematopoiesis.

Steinberg HN, Anderson J, Crumpacker CS, Chatis PA.

Virology. 1993 Mar;193(1):524-7.

PMID:
8438590

Supplemental Content

Loading ...
Support Center